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Context and Objective: In preparation of future prevention trials, we aimed to identify predictors
of 3-year diabetes onset among OGTT- and hyperglycemic clamp-derived metabolic markers in
persistently islet autoantibody positive (autoAb!) offspring and siblings of patients with type 1
diabetes (T1D).
Design: Registry-based study.
Setting: Functional tests were performed in hospital setting.
Participants: Persistently autoAb! first-degree relatives of patients with T1D (n"81; age 5–39
years).
Main outcomemeasures:We assessed 3-year predictive ability of OGTT- and clamp-derivedmark-
ers using receiver operating characteristics (ROC) andCox regression analysis. Areaunder the curve
of clamp-derived first-phase C-peptide release (AUC5–10min; min 5–10) was determined in all rel-
atives and second-phase release (AUC120–150min; min 120–150) in those aged 12–39 years (n"62).
Results: Overall, the predictive ability of AUC5–10min was better than that of peak C-peptide, the
best predictor among OGTT-derived parameters (ROC-AUC [95%CI]: 0.89 [0.80–0.98] vs. 0.81
[0.70–0.93]). Fasting blood glucose (FBG) and AUC5–10min provided the best combination of mark-
ers for prediction of diabetes within three years; (ROC-AUC [95%CI]: 0.92 [0.84–1.00]). In multi-
variate Cox regression analysis, AUC5–10min (P".001) was the strongest independent predictor and
interacted significantly with all tested OGTT-derived parameters. AUC5–10min below percentile 10
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Abbreviations: 95%CI 95%confidence interval; 2h PGOGTT-derived2hours post-glucose
load glycemia; AutoAb(s) Autoantibody (ies); AutoAb! Positivity for IAA, GADA, IA-2A
and/or ZnT8A; AIC Akaike information criterion; AUC5–10min First-phase C-peptide release
during hyperglycemic clamp; AUC120–150min Second-phase C-peptide release during hy-
perglycemic clamp; BMI SDS Body mass index standard deviation score; FBG Fasting blood
glucose; GADA Glutamate decarboxylase autoantibodies; HR High antibody-inferred risk
(relatives positive for IA-2A and/or ZnT8A with at least one other antibody); IA-2A Islet
antigen-2 autoantibodies; IAA Insulin autoantibodies; ICA Islet cell cytoplasmic autoanti-
bodies; IGT Impaired glucose tolerance; IQR Interquartile range; NS Not significant; OGTT
Oral glucose tolerance test; P10 Percentile 10 of the reference population; PPV Positive
predictive value; ROC Receiver operating characteristics; ROC-AUC Area under the curve
from the receiver operating characteristic curve; T1D Type 1 diabetes; ZnT8A Zinc trans-
porter 8 autoantibodies
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of controls was associated with 50–70% progression to T1D regardless age. Similar results were
obtained for AUC120–150min
Conclusions: Clamp-derived first-phase C-peptide release can be used as an efficient and simple
screening strategy in persistently autoAb! offspring and siblings of T1D patients to predict im-
pending diabetes.
Immunointerventions in type 1 diabetic patients haveshown partial and transient efficacy in preserving re-
sidual beta cells, particularly in younger patients with
short diseaseduration, relatively intact functional beta cell
mass at diagnosis and, conceivably, some residual beta cell
regenerative capacity (1, 2). These observations provide a
rationale for planning similar interventions at the preclin-
ical stage in which beta cell function is even better pre-
served (2–4). Given the potential adverse events associ-
ated with immune interventions (5) and the striking
heterogeneity of the underlying disease process (6), the
launch of such studies requires identifying individuals at
very high risk to develop type 1 diabetes (T1D) in the short
term (eg, 70% within 3 years). Antibody screening alone
is not able to select participants with such elevated overall
progression rate (7–10). Multiple genetic risk markers al-
low to identify a subgroupof antibody-positive (autoAb!)
individuals at very high risk but suffer from a low screen-
ing sensitivity (11–14). Metabolic markers such as proin-
sulin: C-peptide ratio and OGTT- or IVGTT-derived pa-
rameters are more sensitive and promising in this respect
(15–21). In a pilot study, we have previously shown that
a low first-phase C-peptide release during hyperglycemic
clamp (AUC5–10min) identifies individuals who progressed
to diabeteswithin 2 years among relatives at high autoAb-
inferred risk (multiple autoAb! and islet antigen 2 au-
toAb!; IA-2A!) (22).
Now, we expand these observations to a larger group
of persistently autoAb! offspring and siblings of type 1
diabetic patients, regardless of the duration of their au-
toAb-positivity, the number or type of antibodies or the
occurrence of dysglycemia, in order to assess whether
clamp-derived C-peptide release might outperform
OGTT-derived parameters in the perspective of selecting
participants in secondary prevention trials with immuno-
intervention. We therefore focused on development of di-
abetes within 3 years after metabolic assessment.
Materials and Methods
Study population
Persistently autoAb! offspring and siblings of patients with
T1D (aged 5–39 years, n " 81) were enrolled among 2225 rel-
atives recruited between November 1998 and July 2011 by the
Belgian Diabetes Registry (10). At inclusion, demographic, per-
sonal and familial data were obtained via a questionnaire and
blood samples were collected for antibody testing. Metabolic
assessment consisted of OGTT and hyperglycemic clamp. Dia-
betes, impaired glucose tolerance (IGT) and impaired fasting
glucosewerediagnosedusingADAcriteria (23). Six relatives had
IGT at inclusion; in two of them, fasting glucose was impaired.
Three of these six relatives developeddiabeteswithin three years.
Bodymass indexwas expressedas standarddeviation score (BMI
SDS) in comparison to age- and sex-matched controls (24). Pro-
gression to overt diabeteswas ascertained through repeated con-
tacts with relatives, Belgian endocrinologists and pediatricians,
self-reporting through yearly questionnaires and a link with the
BDR patient database for new-onset patients. Follow-up started
at entry and ended at diagnosis in case of diabetes or at the last
blood draw. Informed consent was obtained from each relative
or their legal representative.The studyprotocolwas approvedby
the ethics committees of BDR and participating university hos-
pitals and was implemented in accordance with the Helsinki
declaration as revised in 2013 (http://www.wma.net/en/30pub-
lications/10policies/b3/, accessed on September first, 2014).
Oral glucose tolerance test (OGTT)
Blood samples were collected for glucose, proinsulin and C-
peptide analysis before and 30, 60, 90 and 120 minutes after an
oral glucose loadof 1.75mg/kgwithout exceeding themaximum
of 75 g per os. Data on 15 minutes OGTT parameters were
available in 28 persistently autoAb! relatives (35%). Peak C-
peptide was defined as the highest observed C-peptide value be-
tween 0–120 minutes. C-peptide and glucose area under the
curves (AUC) were calculated using the trapezium rule (22).
Hyperglycemic clamp
The test was performed 1–2 weeks after the OGTT as before
(22) but without glucagon injection at min 150. Briefly, after an
overnight fast, a 1.1 mol/l glucose solution was infused (Baxter,
Brussels, Belgium) via the left antecubital vein at time 0. During
the first 14minutes a priming glucose dosewas administered and
glycemia was acutely raised to reach the desired plateau of 10
mmol/l. Thereafter, the hyperglycemic target wasmaintained by
adjusting the glucose infusion rate upon assessment of bedside
blood glucose level every 5 minutes using HemoCue®
(HemoCue, Angelholm, Sweden) or Accu-check® Inform II
(Roche Diagnostics, Mannheim, Germany) glucose monitors.
Blood samples for C-peptide and proinsulin measurements were
collected at time-points 5, 7.5 and 10 minutes to derive AUC5–
10min and at time-points 120, 135 and 150 minutes for the sec-
ond-phaseC-peptide release (AUC120–150min). C-peptide release
was calculated as AUC expressed per minute. In relatives aged
5–11 years (n " 18), only the first-phase (0–10 minutes) of the
clamp was performed.
The intra-individual coefficients of variation for clamp-de-
rived beta cell functionwere respectively 11.8 and 11.7% for the
first- and second-phase C-peptide release (22). The 10th percen-
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tile (P10) of C-peptide AUC obtained from a reference popula-
tion including healthy volunteers (n " 30), antibody-negative
(n " 20) and transiently autoAb! relatives (n " 9) was used as
cutoff value to define lowAUC5–10min (P10" 542 pmol.l
-1.min)
and AUC120–150min (P10" 1776 pmol.l
-1.min) among enrolled
relatives. These three groups did not differ in clamp-derived C-
peptide AUC and shared a low-risk of progression to diabetes
(Supplemental Figure 1) (22). The P10 cutoff was age-indepen-
dent in this control group (not shown). No development of di-
abetes has been reported in the reference population after a me-
dian (interquartile range; IQR) follow-up of 52 (36–132)
months.
Analytical methods
Glucose was assessed with a glucose oxidase method (Vitros
950IC or 5.1 FS Ortho Clinical Diagnostics, Rochester, NY,
USA), C-peptide and proinsulin by time-resolved fluorescence
immunoassay (25). Between-assay coefficients of variation at
low and intermediate levels were 2.4 and 1.3%, respectively for
C-peptide; and 8.8 and 5.5%, respectively for proinsulin. Be-
cause of the high (100%) cross-reactivity betweenC-peptide and
proinsulin assays, free C-peptide levels were obtained by sub-
tracting the proinsulin concentration from the total C-peptide
results (22). Diabetes-associated autoAbs against insulin (IAA)
(26), glutamate decarboxylase (GADA) (27), islet antigen-2 (IA-
2A) (28) and zinc transporter 8 (ZnT8A) (29) were analyzed by
liquid-phase radiobinding assay (30). The radiolabeled antigen
for determination of ZnT8A was obtained by in vitro transcrip-
tion/translation of the dimeric CW-CRZnT8A cDNA construct
incorporating the carboxyterminal cytosolic domains (aa268–
389) of both the Arg325 (CR) and Trp325 (CW) allelic variants.
Resultswere expressedas%bindingof added tracer (10000cpm
/ 50!l forGADA, IA2AandZnT8A; 24000 cpm/ 50!l for IAA).
Between-day coefficients of variationobtained fromserumpools
with antibody levels within the normal range and within the
moderately elevated range were, respectively, 35% (0.3% tracer
binding) and 12% (6.9% tracer binding) for IAA, 12% (2.1%
tracer binding) and 10% (7.1% tracer binding) for GADA, 18%
(0.3% tracer binding) and 9% (2.3% tracer binding) for IA-2A
and 21% (0.7% tracer binding) and 6% (3.9% tracer binding)
for ZnT8A. Diagnostic sensitivity and specificity were, respec-
tively, 64% and 100% for GADA, 48% and 98% for IAA, 72%
and 99% for IA-2A and 50% and 98% for ZnT8A (CRCW) in
the 2012 Islet Autoantibody Standardization Program (IASP).
Cutoff values for autoAb-positivity were determined as the 99th
percentile of autoAb levels in 761 nondiabetic controls; this
amounted to"0.6%tracer binding for IAA,"2.6%forGADA,
" 0.44% for IA-2A. Because ZnT8A levels tended to decrease
with age in control subjects, cutoff values were calculated sep-
arately for theagegroups0–14years ("1.28%)and15–39years
(" 1.02%) (30).
Statistical methods
Proportions were compared using #2 test, with Yates’ cor-
rection or Fischer’s exact test whereas Mann-Witney U or
Kruskal-Wallis test was used for continuous data. To identify
rapid progressors to diabetes, follow-up was truncated at 3
years. ROC analysis was used to compare diagnostic perfor-
mance of metabolic and hormonal parameters individually or in
combination.AUCof theROCcurve (ROC-AUC)with 95%CI,
diagnostic sensitivity and diagnostic specificity were calculated
(31). The cut-off point for optimal sensitivity and specificity was
identified using theYouden index (32). The goodness of fit of the
models was tested using Akaike information criterion (AIC)
which represents an estimate of informationnot explainedby the
model. We selected the most predictive combination of OGTT-
derived parameters based on ROC-AUC and investigated the
most performant model in combination with clamp-derived
markers. Independent predictors of diabetes onset derived from
OGTT and hyperglycemic clamp, and their interactions were
assessed using Cox proportional hazard models. Diabetes-free
survivalwas assessed usingKaplan-Meier analysiswith log-rank
test. Statistical analyses were performed two-tailed by Stata 12
(StataCorp, Texas, USA). A P value # 0.05 or # 0.05/k in case
of k comparisonswas considered statistically significant.Graph-
Pad Prism version 5.00 forWindows (San Diego, CA, USA) was
used for the figures.
Results
Baseline characteristics of 3-year progressors vs.
nonprogressors
Eighty-one persistently autoAb! offspring or siblings
(age 5–39 years) of patients with T1Dwere enrolled. Dur-
ing follow-up (median [interquartile range; IQR]: 20 [12–
28] months), 14 (17%) relatives (including three relatives
with baseline dysglycemia) developed diabetes within
three years. All three relatives with baseline dysglycemia
carried a susceptible HLA-DQ genotype and at least two
autoAbs. Two of them had a low first-phase C-peptide
release during baseline clamp and developed diabetes
within one year; the third with a borderline low value
progressed after 34 months. Among the dysglycemic rel-
atives who did not progress within three years, two single
autoAb! relativeswithout susceptibleHLA-DQgenotype
showed a normal C-peptide response at baseline, despite
occasional dysglycemia.A thirdmultiple autoAb! relative
with susceptibleHLA-DQgenotype and recurrent dysgly-
cemia progressed only after 83.6 months, despite a bor-
derline low AUC5–10min. This person was lean and had a
high insulin-sensitivity as judged from repeatedly low
HOMA2-IR values (0.4–0.5).
Although the vast majority of autoAb! relatives in our
cohort will develop diabetes within 15 years (multiple au-
toAbs: 77%[95%CI: 67%–87%]under age 40 years [n"
169]; 81% [95%CI: 69%–94%] below 10 years [n" 88];
" 1autoAb: 52% [95%CI: 44%–60%] under age 40
years [n " 390]; 74% [59%–89%] under age 10 years
[n" 149]); unpublished data from Belgian Diabetes Reg-
istry) in line with other reports (33), relatives who did
develop diabetesmore than three years after baselinewere
termed ‘nonprogressors’ in this study. Rapid progression
(within three years) indicates rapid development of T1D
aftermetabolic testing and does not necessarily imply rap-
idly progressing beta cell loss. Within the whole group of
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relatives, 73% (49/67) completed the three year follow-
up. Age, BMI-SDS, gender and HbA1c did not differ be-
tween progressors and nonprogressors (Table 1). None of
the offspring of diabetic mothers developed diabetes
within three years (P " .034). Compared with nonpro-
gressors, rapid progressors tended to have higher FBGand
a higher prevalence of ZnT8A (P " .007) and multiple
autoAbs (P" .008), particularly if one of themwas IA-2A
or ZnT8A (P " .004) (10, 11). They did not differ in
fasting insulin or C-peptide levels.
Except for 2h postglucose load glycemia (2h PG),
OGTT-derived parameters were significantly altered in
progressors compared to nonprogressors (FBG: P" .009;
peak C-peptide: P # .001; glucose AUC: P " .015; AUC
C-peptide: P " .003 vs. non progressors). Similarly,
clamp-derived AUC5–10min and AUC120–150min C-peptide
releasewere both lower in progressors (P # .001). The
latter also had more often AUC5–10min or AUC120–150min
below the P10 of the control population (P$ .002, Table
1).
ROC curves and Cox regression analysis
In the age group 5–39 years, analysis of OGTT-derived
markers for participants without missing data revealed
that peak C-peptide performed better than all other pa-
rameters (AUC: 0.81, 95%CI: 0.70–0.93) for prediction
of 3-year diabetes onset in the studypopulation.However,
considering all metabolic parameters individually, we ob-
tained the highest ROC-AUC with AUC5–10min (ROC-
AUC: 0.89; 95%CI: 0.80–0.98) which also yielded the
lowest AIC (Table 2). Considered together, peak C-pep-
tide and glucose AUC performed better than any other
combinations of two OGTT-derived markers (ROC-
AUC: 0.86, 95%CI: 0.77–0.98) and performance was
only slightly improved by introducing one, two or even
three additionalmarkers.When combining clamp-derived
AUC5–10min with the different individual OGTT-derived
parameters, FBG and AUC5–10min was the best combina-
tion of two parameters (not shown) compared with the
best combinations of two, three, four or even all OGTT-
derived markers combined with AUC5–10min (Table 2).
Table 1. Baseline characteristics of the study population
Relatives according to 3-year outcome (5–39 yr)
All relatives Non-progressors Progressors P value
Characteristics (n ! 81) (n ! 67 ) (n ! 14)
Age, years 17 (12–25) 17 (12–26) 19 (10–23) .871
BMI SDS 0.34 (-0.43 – 1.09) 0.35 (-0.29 – 1.06) $0.21 (-1.09 – 0.65) .193
Gender, M/F (ratio) 48/33 (1.5) 40/27 (1.5) 8/6 (1.3) .859
HbA1c, % 5.3 (4.9–5.4) 5.3 (4.9–5.4) 5.3 (5.2–5.6) .394
HbA1c, mmol/mol 34 (30–36) 34 (30–36) 34 (33–38)
Relationship with proband
Sibling, n (%) 38 (47) 32 (48) 6 (43) .738
Offspring father, n (%) 26 (32) 18 (27) 8 (57) 0.055
Offspring mother, n (%) 17 (21) 17 (25) 0 (0) 0.034
Antibodies
IAA, GADA, IA-2A, ZnT8A, % 31/89/54/53 31/88/49a/46b 29/93/79a/86b a 0.045
b 0.007
" 2 autoAb!, n (%) 50 (62) 37 (55) 13 (93) 0.008
HR relativesc, n (%) 47 (58) 34 (51) 13 (93) 0.004
OGTT data
Fasting blood glucose, mmol/liter 4.5 (4.2–4.9) 4.4 (4.1–4.8) 4.9 (4.4–5.3) 0.009
2 h plasma glucose, mmol/liter 5.4 (4.6–6.2) 5.3 (3.9–6.2) 5.7 (5.2–7.2) 0.088
Peak C-peptide, nmol/liter 2.4 (1.8–2.7) 2.5 (1.9–2.8) 1.7 (1.5–2.1) #0.001
Glucose AUC, mmol/liter 6.6 (5.6–7.7) 7.5 (6.6–8.3) 6.4 (5.4–7.4) 0.015
C-peptide AUC, nmol.l-1!min 1.6 (1.3–2.0) 1.8 (1.4–2.2) 1.2 (1.1–1.4) 0.003
Clamp data
C-peptide AUC5–10 min, pmol.l
-1!min 802 (585–1009) 888 (696–1084) 411 (335–590) #0.001
C-peptide AUC120–150 min, pmol.l
-1!min 2405 (1747–3105) 2528 (2199–3182) 1327 (950–1794) #0.001
C-peptide AUC5–10 min, n (%) #P10 17 (21) 8 (12) 9 (64) #0.001
C-peptide AUC120–150 min, n (%) #P10
d 16 (26) 9 (17) 7 (70) 0.002
Follow-up time, months 28 (18–51) 34 (22–62) 20 (12–28) 0.004
BMI SDS: body mass index standard deviation score; HbA1c: glycated hemoglobin; NS: not significant; AUC: area under the curve; P10: 10th
percentile of the control population; IAA: insulin autoantibodies; GADA: glutamate decarboxylase autoantibodies; IA-2A: islet antigen 2
autoantibodies; ZnT8A: zinc transporter 8 autoantibodies; autoAb!: positivity for IAA, GADA, IA-2A and/or ZnT8A; c High antibody-inferred risk
(HR) relatives defined as persistent positivity for IA-2A and/or ZnT8A with at least 1 other autoAb; danalysis restricted to the subset of relatives
aged 12–39 yr (n " 63) with both first- and second-phase C-peptide AUC (10 progressors and 53 non-progressors); data are count (proportion) or
median (interquartile range) unless otherwise stated, threshold for significance P # 0.005/25 or P # 0.002 (Bonferroni correction).
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FBG and AUC5–10min was associated with the lowest AIC
and a similar ROC-AUC (0.92, 95%CI: 0.84–1.00).Indi-
vidually, FBG and AUC5–10min achieved a 50 and 64%
positive predictive value (PPV) respectively, while their
combination yielded 89% PPV (not shown).We obtained
similar findings in the age group 12–39 years, both for
AUC5–10min and AUC120–150min (Supplemental Table 1).
In univariate Cox regression analysis, all metabolic pa-
rameters derived from OGTT or hyperglycemic clamp
were significantly associated with diabetes development
within 3 years (Table 3). However, AUC5–10min outper-
formed each of the OGTT-derived parameters in a two-
by-two multivariate analysis. Moreover, we identified a
significant interaction between all OGTT-derived func-
tional markers and AUC5–10min (Table 3). AUC5–10min
also outperformed the presence of a high-risk autoAbpro-
file in two-by-twomultivariate analysis (P# .001 andP"
.080 respectively; not shown).
C-peptide levels atmin 15duringOGTTwere available
in 35% of the autoAb! relatives, but incremental C-pep-
tide/glucose responses were not significantly correlated
with AUC5–10min (R
2 "0.111; P " .083; not shown).
Kaplan-Meier survival analysis based on C-peptide
release during hyperglycemic clamp
In the relatives aged 12–39 years (n" 62) who under-
went a complete hyperglycemic clamp, clamp-derived C-
peptide release stratified progression to diabetes. Low C-
peptide during at least one clamp phase (#P10) was
associatedwith approximately 50%3-year progression to
diabetes, both before (Figure 1A) and after (Figure 1B)
exclusion of relatives with dysglycemia at baseline (both
P " .001 vs. groups with normal AUC5–10min and
AUC120–150min). When only considering first-phase
C-peptide release in the same age group, more than 70%
absolute risk of diabetes within 3 years was observed in
relatives with AUC5–10min#P10, both in all relatives aged
12–39 years (Figure 1C) and after exclusion of individuals
with baseline dysglycemia (Figure 1D, both P # .001 vs.
groups with normal AUC5–10min). Similar significant dif-
ferences, albeit with somewhat lower overall 3-year pro-
gression rate in case of AUC5–10min#P10, were observed
when the entire groupof relatives aged5–39years (n"81)
was considered before (Figure 1E) or after (Figure 1F)
exclusion of initially dysglycemic individuals (55% and
56% respectively; in both instances P # .001 vs. groups
with normal AUC5–10min). Most relatives who progressed
to diabetes within three years had at least two autoAbs
(13/14; 93%) When considering only multiple autoAb!
relatives, thosewith low clamp-derived first-phase C-pep-
tide release (#P10) also progressed faster to diabetes
(5–39 years: P" .027 vs AUC5–10min%P10; 12–39 years:
P " .005). Similar results were obtained in individuals
with particularly high antibody-inferred risk (IA-2A! or
ZnT8A!plus at least oneother positivemolecular autoAb
(10) (5–39 years: P" .015; 12–39 years: P" .007) (Sup-
plemental Figure 2 showing 84 months follow-up).
Table 2. Receiver operating characteristic analysis in relatives aged 5–39 yr






Fasting blood glucose, mmol.l-1 0.70 (0.53–0.87) 66.9 69 68
2 h PG, mmol.l-1 0.66 (0.48–0.84) 68.8 46 85
Glucose AUC, mmol.l-1!min 0.72 (0.57–0.86) 66.8 85 56
C-peptide AUC, nmol.l-1!min 0.77 (0.63–0.91) 62.7 77 76
Peak C-peptide, nmol.l-1 0.81 (0.70–0.93) 59.6 69 87
Hyperglycemic clamp-derived marker a
C-peptide AUC5–10 min, pmol.l
-1!min 0.89 (0.80–0.98) 48.1 92 76
Combinations of OGTT-derived markers
Best combination of two markers:
peak C-peptide! glucose AUC
0.86 (0.77–0.98) 55.0 84 77
Best combination of three markers:
FBG! peak C-peptide ! glucose AUC
0.88 (0.77–0.99) 53.2 77 89
Best combination of four markers:
FBG! peak C-peptide ! glucose AUC! C-peptide AUC
0.88 (0.77–0.99) 55.0 69 97
All OGTT-derived markers 0.88 (0.77–0.99) 57.0 69 97
Combined OGTT markers ! clamp-derived markers
FBG ! C-peptide AUC5–10 min
b 0.92 (0.84–1.00) 42.4 92 84
Best combination of two markers !
C-peptide AUC5–10 min
0.93 (0.85–1.00) 46.1 85 94
Best combination of three markers !
C-peptide AUC5–10 min
0.93 (0.85–1.00) 44.0 92 82
Best combination of four markers !
C-peptide AUC5–10 min
0.93 (0.85–1.00) 45.9 92 84
All OGTT-derived markers !
C-peptide AUC5–10 min
0.93 (0.86–1.00) 47.8 92 84
AUC: area under the curve; 95%CI: 95% confidence interval; OGTT: oral glucose tolerance test; FBG: fasting blood glucose; 2 h PG: two-hour
post-glucose load glycemia during OGTT; C-peptide AUC5–10 min: C-peptide release during the first-phase (5–10 min) of hyperglycemic clamp; C-
peptide AUC120–150 min: C-peptide release during the second-phase (120–150 min) of hyperglycemic clamp, calculations were done in 75 study
participants with complete data among whom 13 developed diabetes within 3 yr; a second-phase of hyperglycemic clamp was performed only in
relatives aged 12–39 yr (see Supplemental Table 1); b best combination of a single OGTT-derived marker and AUC5–10 min. Data resulted from the
analysis of 13 progressors among 75 relatives with complete dataset.
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After stratificationof the studypopulationaccording to
FBG tertiles, a low first-phase C-peptide release during
clamp conferred a higher 3-year risk of diabetes (median
[95%CI]: 83% [54–100]) to relatives in the upper tertile
(Figure 2C) than to those in the middle or lower tertiles
(Figure 2A and 2B). We observed no difference in pro-
gression rate according to AUC5–10min after stratification
according to tertiles of other OGTT-derived parameters
(not shown). Tertiles of C-peptide release, but not 2h PG,
stratified diabetes risk, both in all autoAb! relatives and
in those with high autoAb-inferred risk. AUC5–10min per-
formed better than OGTT peak C-peptide in this respect
(Supplemental Figure 3).Although theoverall progression
rate to diabetes was higher in relatives with a high-risk
autoAb profile than in all autoAb! relatives, a lowAUC5–
10min (#P10 of controls) was associated with equally fast
progression to diabetes in both groups (Supplemental Fig-
ure 4).
Discussion
In this expanded series of persistently autoAb! siblings
andoffspring of type 1diabetic patientswe confirmed that
individuals who progressed to diabetes within three years
from metabolic testing had significantly lower AUC
5–10min
and/or AUC120–150min during hyperglycemic clamp than
relatives who did not - or only slowly - progress to clinical
onset (22). Consistent with other reports (33), most rapid
progressors to T1D had at least two positive autoAbs,
often comprising IA-2A and/or ZnT8A (10, 11). The ma-
jor finding of this study is that hyperglycemic clamp-de-
rived functional markers (AUC5–10min and AUC120–
150min) outperformed the most informative OGTT-
derived parameters to identify relatives with impending
diabetes regardlessof theautoAb-inferred riskprofile.The
3-year risk conferred by AUC5–10min #P10 of controls
amounted to 50%–70% in the overall autoAb! study
population, reaching up to 83% if FBG was in the upper
tertile. These results suggest that a 10 minutes hypergly-
cemic clamp test, determiningonlyAUC5–10minC-peptide,
is sufficient to identify most rapid progressors and is ap-
plicable andwell accepted over awide age range (22).Our
results were also valid when only relatives with a high
autoAb-inferred risk were considered, indicating that low
clamp-derivedC-peptide release is not a surrogate formul-
tiple autoAbs, but an important additionalmarker to iden-
tify, among individuals who will almost all develop dia-
betes within 15 years (33, 34), those who are closest to
clinical onset.
Table 3. Cox regression analysis assessing independent diabetes prediction ability of OGTT-derived parameters and
first-phase C-peptide release during hyperglycemic clamp and their possible interactions
Univariate analysis Multivariate analysis
Covariates HR (95%CI) P-value HR (95%CI) P-value
Model 1A
FBG 4.166 (1.310–13.255) 0.016 6.382 (1.829–22.265) 0.004
AUC5–10 min 0.995 (0.992–0.998) 0.001 0.994 (0.992–0.997) #0.001
Model 1B
FBG *AUC5–10 min 0.999 (0.999–1.000) 0.002
Model 2A
2hPG 1.521 (1.081–2.141) 0.016 - NS
AUC5–10 min 0.995 (0.992–0.998) 0.001 0.994 (0.991–0.997) #0.001
Model 2B
2hPG *AUC5–10 min 0.999 (0.999–1.000) 0.009
Model 3A
Glucose AUC 1.366 (1.019–1.832) 0.037 1.662 (1.060–2.607) 0.027
AUC5–10 min 0.995 (0.992–0.998) 0.001 0.994 (0.991–0.998) 0.001
Model 3B
Glucose AUC *AUC5–10 min 1.000 (0.999–1.000) 0.011
Model 4A
Peak C-peptide 0.214 (0.067–0.683) 0.009 - NS
AUC5–10 min 0.995 (0.992–0.998) 0.001 0.995 (0.992–0.998) 0.001
Model 4B
Peak C-peptide *AUC5–10 min 0.998 (0.997–0.999) 0.002
Model 5A
C-peptide AUC 0.998 (0.997–1.000) 0.020 - NS
AUC5–10 min 0.995 (0.992–0.998) 0.001 0.995 (0.992–0.998) 0.001
Model 5B
C-peptide AUC *AUC5–10 min 1.000 (1.000–1.000) 0.003
HR: hazard ratio; 95%CI: 95% confidence interval; FBG: fasting blood glucose; AUC5–10 min: C-peptide release during the first-phase (5–10 min) of
hyperglycemic clamp; 2 h PG: two-hour post-glucose load glycemia during OGTT; AUC: area under the curve; NS: not significant.
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Focusingon3-year progression todiabetes – an interval
relevant for prevention studies – constitutes a strength of
this study. Participants were enrolled based on positivity
formolecular antibodieswithout considering cytoplasmic
islet cell antibodies (ICA). The latter test yields only semi-
quantitative results and is not entirely independent of the
molecular antibody markers (10). The relatively small
number of progressors to diabetes within three years is a
major limitation, but we restricted the number of covari-
ates inmultivariate analysis byassessing two-by-twomod-
els to comply with the event–to-variable ratio of Vitting-
hoff (35). We could therefore not adjust for clinical
parameters (age, BMI, relationship to the proband) but
this does not invalidate the comparison with OGTT-de-
rived parameters. Moreover, our survival analyses indi-
cate that our prediction model is equally valid above age
12 years. Our study population was more homogeneous
than that of certain other programs sincewe only included
persistently autoAb! siblings or offspring, but not second-
degree relatives (19). Unlike certain other cohorts (eg,
DAISY, TEDDY, BABYDIAB) (9), relatives were not fol-
lowed from birth on. However, we do not believe this to
Figure 1. Diabetes-free survival after stratification according to clamp-derived C-peptide AUC below or above percentile 10 (P10) of the control
population (see methods) before (panels A, B and C) and after (panels D, E and F) exclusion of relatives with dysglycemia. Panels A (n " 62) and D
(n " 57): AUC5–10 minutes and/or AUC120–150 minutes #P10 (solid line) and AUC5–10 minutes and AUC120–150 minutes "P10 (broken line) in the age
group 12–39 years; panels B (n " 63) and E (n " 57): AUC5–10 minutes #P10 (solid line) and AUC5–10 minutes "P10 (broken line) in the age group
12–39 years; panels C (n " 81) and F (n " 75): AUC5–10 minutes#P10 (solid line) and AUC5–10 minutes "P10 (broken line) in the age group 5–39
years.
Figure 2. Diabetes-free survival in autoAb! relatives stratified according to fasting blood glucose tertiles: First-phase C-peptide release during
hyperglycemic clamp below (solid line) or above (broken line) percentile 10 (P10) of the control population stratified according to the first (panel A;
FBG $ 4.28 mmol.l-1), second (panel B; 4.28 # FBG $ 4.78 mmol.l-1) and third (panel C; FBG " 4.78 mmol.l-1) tertiles of fasting blood glucose.
The numbers in each tertile are slightly different because there were several participants with identical glycemia levels.
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be relevant, since presently inclusion in immunointerven-
tion trials is not considered under age 5 years. Finally, we
could not report C-peptide concentrations 15 minutes
postglucose load duringOGTTwhich have been shown to
be more informative than the value after 30 minutes (36).
As we started to collect these data after this study was
initiated, they are only available in 35% of the partici-
pants. At variance with a previous report (36), we did not
find a significant correlation between the incremental C-
peptide/glucose response 15 minutes postglucose load
duringOGTT,possibly related todifferences in studypop-
ulation and C-peptide range tested (not shown). Finally,
our results need to be confirmed prospectively in an inde-
pendent cohort.
The DPT-1 study group recently reported that in ICA!
individuals with dysglycemia and/or decreased insulin re-
lease during IVGTT, the combination of OGTT-derived
peak C-peptide, 2h PG and C-peptide AUC improved ac-
curacy in predicting progression to T1D (19). Moreover,
IVGTT-derived measurements did not further raise the
predictive ability. In contrast, our results indicate that C-
peptide release under intravenous (IV) glucose stimulation
during a hyperglycemic clamp – the gold standard for
%-cell function (37) – is more accurately predicting rapid
progression to diabetes than the selectedmost informative
OGTT-derivedparameters (2hPG,AUCglucose andpeak
C-peptide) (16, 19), even in individuals with a completely
normal OGTT. The higher reproducibility of the clamp
test as compared with IVGTT may help explain the dif-
ference between both studies (22, 38). In the age group
12–39 years, the diagnostic performance of C-peptide re-
lease under prolonged glycemic stimulation (AUC120–
150min) during a full clamp was not superior to that of
AUC5–10min for predicting rapid progression. Assessment
ofAUC5–10min is applicable on a larger scale than themore
cumbersome full clamp procedure in the age range 5–39
years, relevant for immune interventions, as it can be com-
pleted within 30minutes and does not require adjustment
of the glucose infusion rate after the priming dose. It is also
more reproducible than the 10 minutes IVGTT after glu-
cose bolus (38) and shorter than the 1–3h IVGTT formin-
imal model analysis (39). The introduction of an addi-
tional functional test to the standard clinical OGTT
procedure,which is anywayneeded to detect dysglycemia,
might be considered a disadvantage and an impediment to
the widespread application of such mini-clamps. How-
ever, the latter are in our experience well accepted and
tolerated by relatives, also children, and their better pre-
dictive performance supports their implementation. Since
a low AUC5–10min is also the best prognostic marker in
normoglycemic relatives, a prediction strategy based on
the use of these “mini-clamps” (first 10 minutes) in au-
toAb! individuals opens perspectives for considering us-
ing the development of dysglycemia as surrogate endpoint
in prevention trials (2, 40).
Whether impairment of AUC120–150min during hyper-
glycemic clamp generally precedes the drop inAUC5–10min
could not be determined in the present analysis of baseline
clamps. If proven, this parameter could represent an ear-
lier indicator of beta cell loss as previously suggested (22)
and might become instrumental in predicting diabetes de-
velopment over a longer period. An ongoing longitudinal
study is investigating temporal changes in first- and sec-
ond-phase C-peptide release in relation to diabetes devel-
opment in autoAb! relatives. AUC120–150min also allows
to monitor functional beta cell mass after clinical onset
andwas validated aspredictor of therapeutic response and
outcome measure in tertiary immune intervention trials
and %-cell replacement therapy (2).
In conclusion, a decreased first- and second-phase C-
peptide release during hyperglycemic clamp precedes clin-
ical onset and often dysglycemia in autoAb! relatives.
First-phaseC-peptide release (AUC5–10min) better discrim-
inates rapid (ie, within three years) progressors to diabetes
from slow or nonprogressors than OGTT-derived mea-
sures. A 10minutes mini-clamp procedure is instrumental
in identifying candidates of choice for secondary preven-
tion trialswith immune intervention over awide age range
among autoAb! individuals. Such trials will help define
the minimal functional beta cell mass is needed for ther-
apeutic efficacy in preT1D.
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